Article
FGF21 in ataxia patients with spinocerebellar atrophy and mitochondrial disease.
Clinica chimica acta; international journal of clinical chemistry - 24 Dec 2012
Su Shih-Li, Wang Wen-Fu, Wu Shey-Lin, Wu Hung-Ming, Chang Jui-Chih, Huang Ching-San, Cheng Wen-Ling, Soong Bing-Wen, Lee Yi-Chung, Li Jie-Yuan, Kuo Shou-Jen, Chen Ming, Huang Chie-Ning, Liu Chin-San
Abstract excerpt
BACKGROUND: Serum fibroblast growth factor 21 (FGF21) was proven to be a useful biomarker for the presence of mitochondrial neuromuscular disease. METHODS: In the present study, we used the difference in the serum FGF21 level to differentiate between ataxia patients with hereditary spinocerebellar atrophy (SCA-ataxia) and those with mitochondrial syndrome (Mito-ataxia). Patients with SCA-ataxia (SCA2, SCA3) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.